Graphical Abstract
![](https://wqketang.oss-cn-beijing.aliyuncs.com/zip-unzip/zip-4b493df9-6372-45f6-98a4-95028d6854f5/files/NBE-2024-0052-TOC.jpg?Expires=1725761691&OSSAccessKeyId=STS.NTvdnrExg2Q8mXni5MBFS4XFT&Signature=7%2FJcc0fDwqAnKTMV2If7AldS3ss%3D&security-token=CAISywJ1q6Ft5B2yfSjIr5fDL9TGqKdGhZPTb37fjTUYTsl%2F253ttjz2IHtKenhsBOsbtfk1mG5W5%2FgZlqJ9SptIAEfJa9d99Mz1DOhGltCT1fau5Jko1beHewHKeTOZsebWZ%2BLmNqC%2FHt6md1HDkAJq3LL%2Bbk%2FMdle5MJqP%2B%2FUFB5ZtKWveVzddA8pMLQZPsdITMWCrVcygKRn3mGHdfiEK00he8TouufTinpHMskGA1Aell7Mvyt6vcsT%2BXa5FJ4xiVtq55utye5fa3TRYgxowr%2Fwo0v0YpGya5YzHXwcPskvdKZbo78UqLQlla6w%2BGqFJqvPxr%2Fp8t%2Fx5fWJKAezhVgs8cVM8JOjIqKOscIsiZgsixnGqFV55c8Fdm%2BgUooJVgIMhTnduUfAPJAGOxzJitP%2BUVGGphr60TEnBL4rB5MUctfzRpxSOU77UTzDnGoABjx0vEJuILamchxF1exqHj1VCE2E052J46Bn1Irw8MKor3yWFNG99rnNRPgaw52nntntYhTQQSWjyfWeqfUjdG1F3UfEoXFghVEleJkzBCieeEVuYd8mq%2BJCG%2FtVPgHFaajO6LvKrkDEJ7M1zm9WrQYvS0oVsNAcwKZIgoMmaJGIgAA%3D%3D)
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Malignant tumors remain a serious threat to human health and life and are a major public health problem globally. Herein, we designed and synthesized a novel nucleic acid nanomedicine AS1411-siRNA-LNPs (As@LNPs). Bmi-1 siRNA was coated with cationic liposomes, and a nucleic acid aptamer AS1411 with tumor cell-targeting ability was attached to the outermost layer of the liposomes. The average particle size of As@LNPs was 183 nm, and the polydispersion coefficient was 0.187. The encapsulation rate and drug loading of As@LNPs were 85% and 4.6%, respectively. The average electron mobility of the drug was 2.64 (μ/s)/(V/cm), and the zeta potential of As@LNPs was 33.79 ± 0.78 mV. The microstructure of the nanomedicine was evaluated via transmission electron microscopy. In vitro and in vivo experiments showed that As@LNPs significantly inhibited tumor growth and promoted tumor cell apoptosis. As@LNPs showed favorable biosafety with major tissues and organs, except glomerulus and renal epithelial cells.
P.J. Bates, D.A. Laber, D.M. Miller, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Experimental and Molecular Pathology, 2009, 86(3): 151−164. https://doi.org/10.1016/j.yexmp.2009.01.004
C. Ritchie, B. Doran, K. Shah, et al. Combination of the aptamer AS1411 with paclitaxel or Ara-C produces synergistic inhibition of cancer cell growth. Cancer Research, 2007, 67(9_Supplement): 4818.
D. Jones, D. Dobinson, B. Doran. AS1411, a novel anti-nucleolin aptamer, shows synergy with other anti-cancer drugs in vitro and in vivo in AML models. Cancer Research, 2008, 68(9_Supplement): 5689.
A.V. Molofsky, S. He, M. Bydon, et al. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes &Development, 2005, 19(12): 1432−1437. https://doi.org/10.1101/gad.1299505
N. Gautam, M. Kaur, S. Kaur. Structural assembly of polycomb group protein and insight of EZH2 in cancer progression: A review. Journal of Cancer Research and Therapeutics, 2021, 17(2): 311. https://doi.org/10.4103/jcrt.jcrt_1090_19
S. Dhawan, S.I. Tschen, A. Bhushan. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic β-cell proliferation. Genes &Development, 2009, 23(8): 906−911. https://doi.org/10.1101/gad.1742609
J.J.L. Jacobs, B. Scheijen, J.-W. Voncken, et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes &Development, 1999, 13(20): 2678−2690. https://doi.org/10.1101/gad.13.20.2678
S. Senthil Kumar, S. Sengupta, X.T. Zhu, et al. Diffuse intrinsic pontine glioma cells are vulnerable to mitotic abnormalities associated with BMI-1 modulation. Molecular Cancer Research, 2020, 18(11): 1711−1723. https://doi.org/10.1158/1541-7786.MCR-20-0099
Lu H, Sun H-Z, Li H, et al. The Clinicopathological Significance of Bmi-1 Expression in Pathogenesis and Progression of Gastric Carcinomas. Asian Pac J Cancer Prev, 2012, 13(7): 3437−3441. https://doi.org/10.7314/apjcp.2012.13.7.3437
Zhang X, Hua R, Wang X, et al. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. Oncotarget, 2019, 7(9): 9815−9831. https://doi.org/10.18632/oncotarget.6890
L.B. Song, J. Li, W.T. Liao, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. The Journal of Clinical Investigation, 2009, 119(12): 3626−3636. https://doi.org/10.1172/JCI39374
K.H. Pietiläinen, K. Ismail, E. Järvinen, et al. DNA methylation and gene expression patterns in adipose tissue differ significantly within young adult monozygotic BMI-discordant twin pairs. International Journal of Obesity, 2016, 40(4): 654−661. https://doi.org/10.1038/ijo.2015.221
D.J.Y. Sun, X.J. Xu, X.Y. Fu, et al. Abstract P356: The temporal relationship between body mass index and DNA methylation: Longitudinal epigenome-wide association from the bogalusa heart study. Circulation, 2015, 131: AP356. https://doi.org/10.1161/circ.131.suppl_1.p356
A.A. Wang, S.M. Donovan, M. Teran-Garcia. Monocarboxylate transporter-1 genotype and breastfeeding status protect against elevated BMI in preschool aged Caucasian children. The FASEB Journal, 2012, 26(S1): 647.13. https://doi.org/10.1096/fasebj.26.1_supplement.647.13
Q.H. Dong, R. Kim, N.H. Park, et al. Abstract#5604: Bmi-1 protects human oral epithelial cells from ionizing radiation. Cancer Research, 2009, 69(9_Supplement): 5604.
L.A. Perkins, G.W. Fisher, M. Naganbabu, et al. High-content surface and total expression siRNA kinase library screen with VX-809 treatment reveals kinase targets that enhance F508del-CFTR rescue. Molecular Pharmaceutics, 2018, 15(3): 759−767. https://doi.org/10.1021/acs.molpharmaceut.7b00928
A. Arvey, E. Larsson, C. Sander, et al. Target mRNA abundance dilutes microRNA and siRNA activity. Molecular Systems Biology, 2010, 6: 363. https://doi.org/10.1038/msb.2010.24
J.L. Jiang, X.Y. Cui, Y.X. Huang, et al. Advances and prospects in integrated nano-oncology. Nano Biomedicine and Engineering, 2024, 16(2): 152−187. https://doi.org/10.26599/nbe.2024.9290060
T. Bose, D. Latawiec, P.P. Mondal, et al. Overview of nano-drugs characteristics for clinical application: The journey from the entry to the exit point. Journal of Nanoparticle Research, 2014, 16(8): 2527. https://doi.org/10.1007/s11051-014-2527-7
T. Boettler, B. Csernalabics, H. Salié, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. Journal of Hepatology, 2022, 77(3): 653−659. https://doi.org/10.1016/j.jhep.2022.03.040
V. Colapicchioni, M. Tilio, L. Digiacomo, et al. Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients. The International Journal of Biochemistry &Cell Biology, 2016, 75: 180−187. https://doi.org/10.1016/j.biocel.2015.09.002
T. Ding, J. Guan, M. Wang, et al. Natural IgM dominates in vivo performance of liposomes. J Control Release, 2020, 319: 371−381. https://doi.org/10.1016/j.jconrel.2020.01.018
A. Huang, S.J. Kennel, L. Huang. Immunoliposome labeling: a sensitive and specific method for cell surface labeling. Journal of Immunological Methods, 1981, 46: 141−151. https://doi.org/10.1016/0022-1759(81)90131-9
Z.X. Jiang, J. Guan, J. Qian, et al. Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomaterials Science, 2019, 7(2): 461−471. https://doi.org/10.1039/c8bm01340c
W.L. Liu, A.Q. Ye, F.F. Han, et al. Advances and challenges in liposome digestion: Surface interaction, biological fate, and GIT modeling. Advances in Colloid and Interface Science, 2019, 263: 52−67. https://doi.org/10.1016/j.cis.2018.11.007
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY) (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.